R. Silk

发表

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

M. Polis, H. Masur, P. Pang, 2015, The Lancet. Infectious diseases.

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study

Brad J. Wood, M. Proschan, A. Fauci, 2015, The Lancet.

Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection.

Brad J. Wood, M. Proschan, A. Fauci, 2015, JAMA.

Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse

A. Fauci, H. Masur, P. Pang, 2014, Annals of Internal Medicine.

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Brad J. Wood, M. Proschan, R. Dewar, 2013, JAMA.

Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

H. Masur, S. Bentzen, S. Kottilil, 2017, Annals of internal medicine.

Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.

M. Proschan, M. Polis, H. Masur, 2015, Annals of internal medicine.

Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.

H. Masur, M. McLaughlin, H. Mo, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.

M. Polis, H. Masur, M. McLaughlin, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV

H. Masur, S. Kottilil, C. Hadigan, 2017, The Journal of infectious diseases.

HIV/HCV Co‐infection: Overcoming Barriers to Treatment

R. Silk, C. Gross, S. Kattakuzhy, 2016, The Journal of the Association of Nurses in AIDS Care : JANAC.

Long-Term Changes in Hepatic Fibrosis following Hepatitis C Viral Clearance in Patients with and without HIV

M. McLaughlin, D. Kleiner, S. Kottilil, 2019, Antiviral therapy.

Testosterone in Men With Chronic Hepatitis C Infection and After Hepatitis C Viral Clearance.

M. McLaughlin, T. Stanley, Thomas Mee, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment

H. Masur, D. Sternberg, S. Kottilil, 2021, Journal of addiction medicine.

High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study

M. Proschan, M. Polis, H. Masur, 2015, Hepatology International.

P0875 : Predictors of sustained viral response to 4–6 week duration therapy with ledipasvir + sofosbuvir + GS-9451 +/− GS-9669 in early and advanced fibrosis (NIH/UMD synergy trial)

H. Masur, H. Mo, P. Pang, 2015 .

Suboptimal Uptake, Retention, and Adherence of Daily Oral Prexposure Prophylaxis Among People With Opioid Use Disorder Receiving Hepatitis C Virus Treatment

H. Masur, D. Sternberg, S. Kottilil, 2021, Open forum infectious diseases.

Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs.

H. Masur, Junfeng Sun, D. Sternberg, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV

H. Masur, D. Sternberg, S. Kottilil, 2022, Open forum infectious diseases.

Hepatitis C cure and medications for opioid use disorder improve health-related quality of life in patients with opioid use disorder actively engaged in substance use.

Max Spaderna, R. Silk, S. Narayanan, 2022, The International journal on drug policy.

Collocation of Buprenorphine with HCV treatment to improve adherence and reduce harm in PWID with HCV: Preliminary data from the ANCHOR study

H. Masur, D. Sternberg, S. Kottilil, 2018 .

Effect of HIV on liver fibrosis among HCV-infected African Americans.

H. Masur, S. Henn, S. Kottilil, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

LP09 : High efficacy of retreatment with ledipasvir and sofosbuvir in HCV patients who failed initial short course therapy with combination DAA regimens (nih synergy trial)

H. Masur, M. McLaughlin, S. Kottilil, 2015 .